investigated the utility of Treg in CRC in 2002 and discovered that Treg is induced by TGF-β in human colorectal cancer without contact and mediates immune escape to protect tumor cells by inhibiting CTL activation and subsequently acting as a mechanism to inhibit tumor cell destruction (46). This evidence concerns the gene TGFB1 and neoplasm.